Latest Europe News

ECS Botanics has reported a return to profitability and positive cash flow in the first half of FY26, driven by a strategic shift to branded products and major infrastructure expansion.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

Ainsworth Game Technology reported a 10% revenue increase to AUD 290.8 million for 2025 but posted a net loss of AUD 19.2 million, driven by a significant goodwill impairment and foreign currency headwinds. The company’s strategic investments and market challenges set the stage for a pivotal year ahead.

Clarity Pharmaceuticals has reported a steep 136% increase in its half-year loss to $55.6 million, alongside the closure of its European subsidiary, signaling a challenging period for the ASX-listed biotech.

Rubicon Water reported a 9.4% revenue decline to $29 million and a net loss of $6.4 million in the first half of FY26, driven by a sharp drop in ANZ hardware sales. The company anticipates a rebound in Asia in the second half, despite ongoing foreign exchange headwinds.

Anteris Technologies Global Corp. posted a $94.2 million loss for 2025 amid a 29% revenue decline, while progressing its pivotal DurAVR THV clinical trial and securing $320 million in early 2026 financings.

4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.

SomnoMed Limited has reported a return to profitability for the half-year ending December 2025, posting a $792,000 net profit after tax on the back of a 13% revenue increase. Despite the positive turnaround, the company has elected not to pay an interim dividend.

Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.

Shriro Holdings reported solid half-year growth with revenue up 8.4% and NPAT rising 10%, underpinned by strong BBQ and kitchen appliance sales. The company reaffirmed its EBITDA guidance and announced a $15 million off-market share buy-back for FY26.

Biotron Limited reported a half-year loss as it completed the acquisition of Sedarex Limited and advanced its Hepatitis B drug candidate BIT-HBV001, backed by a $2.5 million capital raise. The company faces material uncertainty over its going concern status, hinging on securing further funding.

Dubber Corporation reported a 9% revenue decline to $18.7 million for the half-year ending December 2025, alongside a 65% reduction in net loss. The company pursues growth through AI innovation and cost efficiencies while navigating ongoing legal proceedings.